BridgeMD
TAR-0520 gel in Hand and Foot Syndrome
EU CTIS ID: 2025-524008-32-00
What this study is testing
Safety of TAR-0520 Gel in colorectal or breast cancer patients treated with capecitabine.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Male or female, who is at least 18 years of age or older at screening visit
- Medical diagnosis of breast or colorectal cancer planned to be treated with capecitabine monotherapy, either in adjuvant/neoadjuvant or palliative setting
- Starting capecitabine at a dose ≥ 1000 mg/ m² twice daily every 2 out of 3 weeks as single-agent chemotherapy
You likely can't join if
- Patient with a medical history of capecitabine treatment
- Patient with pre-existing grade 2 or higher neuropathy confounding assessment of HFS
- Patient with Raynaud’s syndrome or other vascular peripheral disorders
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.